11 Jan 2021 --- Aker BioMarine has teamed up with Medical Food Solutions Research to develop its lysophosphatidylcholine (LPC)-bound EPA and DHA ingredient Lysoveta into pharmaceutical therapies. This is the first commercial pharmaceutical agreement Aker BioMarine has entered since it launched the business segment Lysoveta and product bearing the same name last November.